Novaliq
Novaliq is a private German biopharmaceutical company developing preservative-free ophthalmic therapeutics based on its proprietary EyeSol® water-free drug-delivery platform, commercializing FDA-approved dry eye treatments (VEVYE and MIEBO) via global licensing partnerships with major eyecare companies.
- Company typePrivate
- Founded2007
- HeadquartersHeidelberg, Germany
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What Novaliq does
Novaliq GmbH is a Heidelberg, Germany-based biopharmaceutical company founded in 2007 that develops and commercializes ocular therapeutics built on its proprietary EyeSol® water-free drug-delivery platform. EyeSol® uses semifluorinated alkanes — primarily perfluorohexyloctane — as the carrier medium instead of water, enabling preservative-free, micro-dosed topical ophthalmic formulations with enhanced corneal penetration, longer ocular surface residence time, and no vision blurring. The company's portfolio includes two FDA-approved prescription products launched in 2023 — CyclASol® (cyclosporine 0.1%, marketed as VEVYE™ in USA/Canada and Vevizye® in Europe) and NOV03 (perfluorohexyloctane, marketed as MIEBO™ in USA/Canada and Heng Qin® in China) — both for dry eye disease, plus the over-the-counter NovaTears® / NovaTears®+Omega-3 line commercialized since 2013.
The company operates an asset-light, licensing-driven business model: prescription products are developed in-house through Phase 3 and then out-licensed by geography to established ophthalmic commercial partners — Bausch + Lomb and Harrow in USA/Canada, Laboratoires Théa in Europe/MENA, Senju in Japan, and Jiangsu Hengrui in China — generating upfront payments, development and regulatory milestones, and tiered royalties on net sales. OTC products are distributed through Ursapharm in Europe (under the EvoTears® brand across 17 countries) and AFT Pharmaceuticals in Australia/New Zealand (PBS-listed since 2018). Novaliq also pursues adjacent ophthalmic indications through a glaucoma joint venture (Betaliq Inc., with BLP Management Group), a diabetic retinopathy R&D program, and a dermatology spin-off (Dermaliq Therapeutics), with FDA IND clearance in January 2026 to advance NOV05 into Phase II for non-infectious anterior uveitis.
Novaliq is privately held, with dievini Hopp BioTech Holding as long-term anchor shareholder (lead investor across multiple financing rounds totaling approximately $115 million since inception, including a $53 million round in October 2018 and a $15 million round in April 2022). The company maintains a U.S. subsidiary (Novaliq Inc., Cambridge, MA, established January 2018) and a lean headcount of 51–100 employees, with clinical execution supported by leading ophthalmic CRO Ora, Inc. and academic collaborations with the University of Cologne, Queen's University Belfast, and University of Auckland. Customer reach is global, spanning North America, Europe, MENA, China, Japan, Australia, and New Zealand.
Novaliq firmographics
Firmographics- Name
- Novaliq
- Legal name
- Novaliq GmbH
- Website
- https://novaliq.com
- Company type
- Private
- Founded year
- 2007
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Novaliq is a private German biopharmaceutical company developing preservative-free ophthalmic therapeutics based on its proprietary EyeSol® water-free drug-delivery platform, commercializing FDA-approved dry eye treatments (VEVYE and MIEBO) via global licensing partnerships with major eyecare companies.
- Ownership category
- akta.pro rank
Novaliq industry classification
Industry- Product category
- Ophthalmic Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Ophthalmology Pharmaceuticals (HLAIAAAL)
- akta.pro secondary industry
- Ophthalmology Specialty Pharmaceuticals (HLAIACAK)
Keywords
Where Novaliq is headquartered
LocationHeadquarters
- HQ city
- Heidelberg
- HQ country
- Germany
- HQ region
- Europe
Offices2 records
Markets served
Novaliq business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
Revenue model
- Licensing and Royalty Revenue: Novaliq generates revenue through licensing agreements with pharmaceutical partners for development and commercialization rights. Partners pay upfront payments, development/regulatory milestones, and ongoing royalties on net sales.
- Direct Product Revenue (Europe/Australasia): NovaTears and NovaTears+Omega-3 are commercialized through distribution partners (Ursapharm in Europe, AFT Pharmaceuticals in Australia/New Zealand) generating product revenue streams.
Go-to-market motion2 records
Distribution channels7 records
Marketing channels5 records
Novaliq product offering
Product offeringCore offering
Novaliq develops and commercializes first- and best-in-class ocular therapeutics based on its proprietary EyeSol® water-free technology platform. The company manufactures prescription pharmaceuticals (CyclASol/VEVYE/Vevizye and NOV03/MIEBO) and over-the-counter eye drops (NovaTears, NovaTears+Omega-3) for the treatment of dry eye disease and meibomian gland dysfunction, licensing global commercialization rights to major pharmaceutical partners while generating revenue through upfront payments, milestones, and royalties.
Product overview
Novaliq is a biopharmaceutical company focused on ophthalmology, offering a portfolio of prescription and over-the-counter eye disease treatments. The product portfolio centers on two proprietary technology platforms: EyeSol® water-free technology (used by CyclASol®/VEVYE™/Vevizye®) and perfluorohexyloctane-based formulations (used by NOV03/MIEBO™/Heng Qin® and NovaTears®). CyclASol® and NOV03 represent the company's flagship prescription pharmaceuticals approved for dry eye disease treatment, while NovaTears® and NovaTears®+Omega-3 serve the OTC market. The company also maintains a pipeline including BTQ 1901 and BTQ 1902 for glaucoma through its Betaliq subsidiary.
Differentiator
Problem solved
Functional benefit
Brands
- NovaTears: First water-free eye drop based on EyeSol for treatment of dry eye disease. CE certified since 2013, commercialized in Europe (as EvoTears) and Australia/New Zealand
- NovaTears+Omega-3
- CyclASol
- NOV03
- VEVYE
- MIEBO
- EvoTears
- EyeSol
Products and services
- CyclASol® (VEVYE™ in US/Canada, Vevizye® in Europe) Cyclosporine ophthalmic solution 0.1% based on EyeSol® water-free technology, an anti-inflammatory treatment for dry eye disease indicated for both signs and symptoms. FDA approved May 30, 2023 and EC approved October 2024.
- NOV03 (MIEBO™ in US/Canada, Heng Qin® in China) Perfluorohexyloctane ophthalmic solution based on EyeSol® technology, the first FDA-approved treatment that directly targets tear evaporation for dry eye disease associated with meibomian gland dysfunction.
- NovaTears® Perfluorohexyloctane-based water-free eye drop for treatment of dry eye disease. CE certified since 2013, commercialized in Europe (as EvoTears) and Australia/New Zealand (PBS listed).
- NovaTears®+Omega-3 Eye drop formulation containing high dose of algae-derived omega-3 fatty acids (0.2%) combined with water-free EyeSol® technology platform for enhanced dry eye treatment.
- EvoTears® European brand name for NovaTears® (perfluorohexyloctane) based on water-free EyeSol® technology for dry eye treatment, distributed in 17 European countries including Germany, France, UK, Spain, Italy, Benelux, Poland, and Switzerland.
- BTQ 1902 Glaucoma treatment candidate (timolol in EyeSol) being developed by Betaliq Inc., a Novaliq joint venture with BLP Management Group, focused on ophthalmic beta-blockers using EyeSol water-free technology.
- BTQ 1901 Novel ophthalmic beta-blocker candidate in the Novaliq/Betaliq pipeline for glaucoma treatment using EyeSol technology.
Quantifiable outcome
- NOV03 showed statistically significant improvement in total corneal fluorescein staining at Day 15 (p=0.001) and Day 57 (p<0.001) compared to control in Phase 3 GOBI trial.
- +4 more outcomes
Companies that use Novaliq
Customer profileNamed customers3 records
Segments4 records
Ideal customer profiles3 records
Novaliq technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Novaliq partnerships and signals
Strategic signalPartnerships
13 partnerships are on record, tiered core and minor.
- Laboratoires ThéacoreEuropean Commission approved Vevizye (ciclosporin 0.1% eye drops solution) and partnership with Théa for commercialization in Europe and selected MENA countries. Théa is the leading independent eye care group in Europe.
- HarrowcoreHarrow acquired U.S. and Canadian commercial rights for VEVYE (cyclosporine ophthalmic solution) 0.1% from Novaliq. VEVYE is the first and only cyclosporine-based product indicated for treatment of both signs and symptoms of dry eye disease. FDA approved May 30, 2023.
- Senju Pharmaceutical Co., Ltd.coreLicense agreement for NOV03 (perfluorohexyloctane ophthalmic solution) development, manufacturing, and commercialization in Japan. Senju is a research-based Japanese pharmaceutical company focusing on ophthalmology.
- Bausch + LombcoreExclusive license agreement for NOV03 (perfluorohexyloctane) development and commercialization in USA and Canada. Bausch + Lomb acquired rights in December 2019. MIEBO received FDA approval in May 2023 for treatment of signs and symptoms of dry eye disease associated with meibomian gland dysfunction. It is the first and only FDA-approved treatment that directly targets tear evaporation.
- Jiangsu Hengrui PharmaceuticalscoreStrategic collaboration for NOV03 and CyclASol in China (mainland, Hong Kong, Macau, Taiwan). Hengrui received exclusive rights to develop, manufacture, and commercialize both drugs. Novaliq eligible for upfront payment of up to $9 million, milestone payments up to $156 million, plus tiered royalties. Hengrui is a leading biopharma in China with $2.5 billion annual net sales in 2018.
- Betaliq Inc.coreJoint venture with BLP Management Group in Tampa, Florida to develop ophthalmic beta-blockers using EyeSol technology. Betaliq developing BTQ 1901 (novel beta-blocker) and BTQ 1902 (timolol in EyeSol) for glaucoma treatment. Series A financing completed. Phase 2 clinical trial initiated April 2021.
- NicoxminorResearch collaboration for development of novel topical ophthalmic formulations of Nicox's NO-donating PDE5 inhibitors based on EyeSol technology for lowering intraocular pressure (IOP) in glaucoma treatment.
- UrsapharmcoreCommercialization partner for EvoTears (perfluorohexyloctane) in Europe. EvoTears launched in 17 European countries including Germany, France, UK, Spain, Italy, Benelux, Poland, and Switzerland. Also distributed as HYLO LIPID in France and Hycosan Shield in UK.
- AFT PharmaceuticalscoreDistribution partner for NovaTears and NovaTears+Omega-3 in Australia and New Zealand. Products are PBS listed in Australia since September 2018. AFT is an ASX/NZX listed company and leader in lubricating eyecare category in Australia.
- Prof. Dr. med. Claus CursiefenminorAcademic partner at University of Cologne for ophthalmic drug delivery research for anterior segment of eye with special focus on dry eye disease.
- Prof. Heping XuminorAcademic partner at Queen's University for retina diseases research.
- Dr. Ilva RupenthalminorAcademic partner at University of Auckland for drug delivery technologies and ocular therapeutics research.
- Ora, Inc.coreWorld's leading full-service ophthalmic CRO conducting clinical trials for CyclASol ESSENCE-2 trial in approximately 25 U.S. clinical centers with approximately 834 subjects.
Scale indicators7 records
Recent moves6 records
Expansion highlights6 records
Novaliq competitors and assessment
Company assessmentDirect peers
- Bausch + Lomb (Bausch Health): Global ophthalmology major that licenses NOV03/MIEBO from Novaliq for US/Canada. Compares as a peer because it operates in the same Rx ophthalmology commercial channel and competes for physician share-of-voice in dry eye with Novaliq's other drug VEVYE.
- Harrow Health: US-focused ophthalmic pharmaceutical company that licenses and commercializes VEVYE in US/Canada. Highly comparable as a recent-stage commercializer of branded ophthalmology specialty products with similar GTM to eye-care practitioners.
- Laboratoires Théa: Leading independent European eye-care group that licenses Vevizye from Novaliq for EU/MENA. Direct peer via the partnership, and comparable as a specialty ophthalmology company operating with independent commercial reach across European eyecare channels.
Regional players
- Senju Pharmaceutical: Japanese research-based ophthalmology company licensing NOV03 for the Japan market. Comparable as a regionally-dominant ophthalmic pharma partner but operates primarily in Asia rather than directly competing with Novaliq elsewhere.
Emerging players
- Aldeyra Therapeutics: US clinical-stage biotech developing novel reproxalap for dry eye disease. Comparable as an emerging ophthalmology specialty challenger pursuing novel mechanisms against the same DED market Novaliq targets with MIEBO/VEVYE.
- Oyster Point Pharma: US specialty ophthalmic company that developed Tyrvaya for dry eye disease before being acquired. Comparable as a recent-stage innovator with a single specialty ophthalmology product reaching commercialization.
- Nicox: European ophthalmic R&D company developing NO-donating therapeutics including via collaboration with Novaliq's EyeSol. Comparable as a clinical/specialty ophthalmology company and an actual development partner with overlapping technology interests in glaucoma.
- Kala Pharmaceuticals: Specialty ophthalmic company that developed Eysuvis for dry eye disease flares. Comparable as a single-asset-focused DED challenger that targeted the same underserved prescriber channel.
Broad incumbents
- Aerie Pharmaceuticals (Alcon): Pre-acquisition Aerie was a specialty ophthalmology player focused on glaucoma; acquired by Alcon in 2022. Comparable as a specialty ophthalmic pharma company with branded Rx products targeting the same physician call-point Novaliq pursues.
- Allergan / AbbVie: Maker of Restasis, the legacy cyclosporine dry-eye therapy that VEVYE now competes against directly. Broad incumbent in ophthalmology Rx, providing the entrenched benchmark Novaliq is displacing.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Novaliq social profiles
Digital presenceNovaliq financial estimates
Financial estimateRevenue estimate
Valuation estimate
Novaliq leadership team
Management profileNumber of profiles
Profiles8 records
Novaliq subsidiaries and ownership
Company hierarchySubsidiaries2 records
Novaliq funding detail
Funding detailFunding overview
Funding rounds6 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Novaliq M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Novaliq
What does Novaliq do?
Novaliq develops and commercializes first- and best-in-class ocular therapeutics based on its proprietary EyeSol® water-free technology platform. The company manufactures prescription pharmaceuticals (CyclASol/VEVYE/Vevizye and NOV03/MIEBO) and over-the-counter eye drops (NovaTears, NovaTears+Omega-3) for the treatment of dry eye disease and meibomian gland dysfunction, licensing global commercialization rights to major pharmaceutical partners while generating revenue through upfront payments, milestones, and royalties.
Is Novaliq a public or private company?
Novaliq is a private company. It is classified as venture growth investor backed and is currently operating.
When was Novaliq founded?
Novaliq was founded in 2007. It employs 51 to 100 people.
Where is Novaliq based?
Novaliq is headquartered in Heidelberg, Germany, in the Europe region.
How does Novaliq make money?
Two revenue lines are on record. Licensing and Royalty Revenue is the primary driver. The others are direct Product Revenue (Europe/Australasia).
Who are Novaliq's main competitors?
Direct peers on record are Bausch + Lomb (Bausch Health), Harrow Health and Laboratoires Théa. Senju Pharmaceutical is listed as a regional player. Emerging players are Aldeyra Therapeutics, Oyster Point Pharma, Nicox and Kala Pharmaceuticals. Broad incumbents are Aerie Pharmaceuticals (Alcon) and Allergan / AbbVie.
Does Novaliq have an API?
No public API is recorded for Novaliq.
What industry is Novaliq in?
Novaliq's product category is Ophthalmic Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAL, Ophthalmology Pharmaceuticals, with a secondary code of HLAIACAK, Ophthalmology Specialty Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.